Psychotropic drug treatments for people with autism and other developmental disorders: a primer for practicing behavior analysts.

Weeden et al. (2010) wrote a plain-language guide for BCBAs who work with clients taking behavior meds. The paper explains common psychotropic drugs, why doctors prescribe them, and how behavior analysts can help monitor effects.

It covers autism and other developmental disabilities. The goal is smoother teamwork between prescribers and behavior analysts.

The review found that BCBAs often feel left out of medication decisions. Yet their data can show if a drug helps or hurts client behavior.

The authors give a simple rule: collect baseline data, share it before any med change, and keep tracking after the change.

Henderson et al. (2023) extends this message to all autism teamwork, not just pills. They add modern ethics checklists and show how to run team meetings.

Gasiewski et al. (2021) narrows the lens to BCBA-OT pairs. They give step-by-step scripts for sharing goals and splitting tasks, proving the 2010 idea works across disciplines.

Rieth et al. (2022) supplies fresh data: adults with IDD get more behavior meds when they live in group homes with few choices. This supports Marc’s call for behavior data; your graphs can reveal if less restrictive settings cut drug need.

Matson et al. (1999) sounds an alarm that still rings today: most direct-support staff feel clueless about psychotropic meds. Marc et al. offers the training content these staff said they never got.

You already take data every session. This paper tells you to time-stamp that data around med changes and email it to the prescriber. One clear graph can replace pages of vague “he seems calmer” notes and leads to faster, better drug decisions.